Oral Tranexamic Acid Versus Diosmin for Treatment of Menorrhagia in Women Using Copper IUD

Ain Shams University100 enrolled

Overview

To compare the efficacy of tranexamic acid and diosmin in reducing menstrual blood loss in women having Intra Uterine Contraceptive Device (IUD) and suffer from menorrhagia.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

100

Conditions

Menorrhagia

Interventions

Tranexamic AcidDRUG

use tranexamic acid oral tablets 500 mg two tablets every six hour with the onset of the first day of menstrual cycle till the end of bleeding then The amount of menstrual flow will be calculated by the PBAC

DiosminDRUG

use diosmin oral tablets 500 mg t.d.s (three times daily) with the onset of the first day of menstrual cycle till the end of bleeding.then The amount of menstrual flow will be calculated by the PBAC

Eligibility

Sex: FEMALEMin age: 20 YearsMax age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Women complaining from an menorrhagia secondary to a current copper IUD use. * Age: 20-40years. * Menorrhagia , will be defined as a PBAC-Score greater than 100. * No systemic causes of abnormal uterine bleeding as hypertension and hemorrhagic blood diseases. * No other local causes of abnormal uterine bleeding as, (fibroid, adenomyosis, polyps). * No drugs decreasing blood coagulation. * Well fitted IUD not misplaced. Exclusion Criteria: * Age \<20y and \>40y. * Irregular menstrual cycle. * Presence of systemic causes of abnormal uterine bleeding as hypertension and hemorrhagic blood diseases. * Presence of other local causes of abnormal uterine bleeding as, (fibroid, adenomyosis, polyps). * Taking drugs decrease blood coagulation. * Misplaced IUD.

Locations (1)

Ahmed Alanwar

Cairo, Cairo Governorate, Egypt

RECRUITING

Outcomes

Primary Outcomes

The amount of reducing heavy menstrual flow will be calculated by the PBAC.

measure the bleeding rate will be by the pictorial blood assessment chart (PBAC).

Time frame: the first 24hours

Central Contacts

ahmed alanwar, MD

CONTACT

+201111486669 eladwar@hotmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.